STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRSP
  4. [Form 4] CRISPR Therapeutics AG Insider Trading Activity

CRSP CEO reports RSU vesting and tax sale to cover withholding

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CRISPR Therapeutics (CRSP) Form 4: On October 16, 2025, the CEO and director reported the vesting and settlement of 100,000 restricted stock units into common shares. On October 17, 2025, 50,895 common shares were sold at $67.91 to cover tax withholding mandated by company policy. Following these transactions, holdings were 254,201 common shares directly and 85,662 indirectly via The Kulkarni 2023 GRAT. The RSU grant leaves 300,000 RSUs scheduled to vest annually through October 2028.

Positive

  • None.

Negative

  • None.

Insights

Routine RSU vesting with tax sale; neutral governance signal.

The CEO converted 100,000 RSUs into common shares on October 16, 2025, then sold 50,895 shares at $67.91 on October 17, 2025 to satisfy tax withholding under a mandated policy. Such sales are administrative and do not reflect discretionary trading intent.

Post-transaction holdings totaled 254,201 directly and 85,662 indirectly via The Kulkarni 2023 GRAT. The underlying award originally covered 400,000 shares, with equal tranches vesting on October 16 each year from 2025 to 2028. Actual market impact depends on normal trading volumes and holder decisions.

Insider Kulkarni Samarth
Role Chief Executive Officer
Sold 50,895 shs ($3.46M)
Type Security Shares Price Value
Sale Common Shares 50,895 $67.91 $3.46M
Exercise Restricted Stock Units 100,000 $0.00 --
Exercise Common Shares 100,000 $0.00 --
holding Common Shares -- -- --
Holdings After Transaction: Common Shares — 254,201 shares (Direct); Restricted Stock Units — 300,000 shares (Direct); Common Shares — 85,662 shares (Indirect, The Kulkarni 2023 GRAT)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on October 16, 2024 with respect to 400,000 Common Shares, with (i) one quarter of the shares vesting on October 16, 2025, (ii) one quarter of the shares vesting on October 16, 2026, (iii) one quarter of the shares vesting on October 16, 2027, and (iv) one quarter of the shares vesting on October 16, 2028.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kulkarni Samarth
(Last) (First) (Middle)
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
(Street)
BOSTON MA 02127
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
10/16/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 10/16/2025 M 100,000 A (1) 305,096 D
Common Shares 10/17/2025 S 50,895(2) D $67.91 254,201 D
Common Shares 85,662 I The Kulkarni 2023 GRAT
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 10/16/2025 M 100,000 (3) (3) Common Shares 100,000 (1) 300,000 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
2. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
3. This restricted stock unit award was granted on October 16, 2024 with respect to 400,000 Common Shares, with (i) one quarter of the shares vesting on October 16, 2025, (ii) one quarter of the shares vesting on October 16, 2026, (iii) one quarter of the shares vesting on October 16, 2027, and (iv) one quarter of the shares vesting on October 16, 2028.
/s/ Elizabeth Ryland Waldinger, attorney-in-fact 10/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did CRSP’s CEO report on this Form 4?

The CEO reported settlement of 100,000 RSUs into common shares on October 16, 2025 and a tax-withholding sale of 50,895 shares on October 17, 2025.

At what price were CRSP shares sold to cover taxes?

Shares were sold at $67.91 per share to satisfy tax withholding linked to the RSU vesting.

How many CRSP shares does the CEO hold after the transactions?

Post-transaction holdings are 254,201 common shares directly and 85,662 indirectly via The Kulkarni 2023 GRAT.

How many RSUs remain from the CEO’s award at CRSP?

The filing shows 300,000 RSUs remaining from a 400,000-share award.

What is the vesting schedule for the RSUs at CRSP?

One-quarter vested on October 16, 2025, with additional quarters vesting on October 16 of 2026, 2027, and 2028.

Was the CRSP share sale discretionary?

No. The sale was mandated by the company’s RSU Settlement Policy to cover tax withholding.